Hypoxia clinical trials at UCLA
3 research studies open to eligible people
Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients
open to eligible people ages 18 years and up
A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.
Los Angeles, California and other locations
Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)
open to eligible people ages up to 17 years
This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest. The study team hypothesizes that longer durations of cooling may improve either the proportion of children that attain a good neurobehavioral recovery or may result in better recovery among the proportion already categorized as having a good outcome.
Los Angeles, California and other locations
Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19
open to eligible people ages 18 years and up
This study seeks to define the ultrasound profile of patients with COVID-19, and document the progression of these ultrasound findings to develop prognostication and clinical decision instruments that can help guide management of patient with COVID-19. Primary aims include the development of ARDS, refractory hypoxemia, acute cardiac injury, pulmonary embolism, pneumothorax or death. Secondary aims include potential change in CT and plain film utilization given the use of POCUS, as well as emergency department and inpatient LOS (length of stay).
Los Angeles, California and other locations
Our lead scientists for Hypoxia research studies include Anil Sapru, MD George Lim, MD.
Last updated: